Alterations in angiogenic growth factors and neuronal nitric oxide synthase expression in chronic cavernosal ischemia.
Our aim was to study anatomical and molecular changes at varying time points after the induction of cavernosal ischemia (CI) in a rabbit model of arteriogenic erectile dysfunction. Tissue structure and the expression of angiogenic and neurogenic genes were examined using immunostaining and reverse transcription-polymerase chain reaction (RT-PCR) analyses. We found a progressive increase of erectile connective tissue together with a decrease in smooth muscle cell content as the duration of CI increased. Immunohistochemical staining showed an increase in vascular endothelial growth factor (VEGF) levels at the early stages and a decrease at the later stages of ischemia. RT-PCR analysis of VEGF and neuronal nitric oxide synthase (nNOS) confirmed these results and showed nearly a two-fold increase in VEGF and nNOS mRNA levels in the early stages of CI with a decrease at the later stages of CI. On the other hand, mRNA levels of VEGF receptor, KDR, decreased approximately by 50% over the course of CI. Our studies showed that the cellular and molecular responses of the erectile tissue to short-term ischemia are different than those seen after long-term ischemia. The dramatic reduction in KDR expression suggests that the cavernosal endothelium is very sensitive to ischemia. The similar changes in VEGF and nNOS expression over the course of CI suggest a tissue-defensive mechanism to CI via the VEGF and NO pathways. Taken together, this study suggests that supplementation of VEGF at earlier stages of ischemia may restore the damaged endothelial cells of the corpus cavernosum and support tissue perfusion.
Urology Department Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
T
T
Wang
S
S
Soker
A
A
Atala
M B
MB
Siroky
K M
KM
Azadzoi
D000375:Aging / Q000502:physiology; D000818:Animals; D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D006439:Hemodynamics / Q000502:physiology; D007150:Immunohistochemistry; D007511:Ischemia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D018919:Neovascularization, Physiologic / Q000235:genetics / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000378:metabolism*; D052248:Nitric Oxide Synthase Type I; D010413:Penis / Q000098:blood supply* / Q000254:growth & development / Q000473:pathology; D011817:Rabbits; D040262:Receptors, Vascular Endothelial Growth Factor / Q000096:biosynthesis; D012039:Regional Blood Flow / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; D040262:Receptors, Vascular Endothelial Growth Factor